SRNE - Sorrento Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue8,1524,5903,825
Cost of Revenue8111,9502,043
Gross Profit7,3412,6401,782
Operating Expenses
Research Development42,17531,34323,983
Selling General and Administrative16,09820,1329,987
Non Recurring45,00024,013209
Total Operating Expenses104,11876,64536,524
Operating Income or Loss-96,777-74,005-34,742
Income from Continuing Operations
Total Other Income/Expenses Net33,11965,93812
Earnings Before Interest and Taxes-63,223-12,108-34,730
Interest Expense1,6101,6521,629
Income Before Tax-64,833-13,760-36,359
Income Tax Expense-89636,314-1,702
Minority Interest6,465-4,214-4,214
Net Income From Continuing Ops-60,488-49,852-34,657
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-60,923-45,811-34,657
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-60,923-45,811-34,657